# Clinical Application of an Oral Liquid Bandage (ORAPLA) for Traumatic and Surgical Oral Mucosal Wounds: A Technical Note

**Authors:** Hiroshi Furuta, Atsushi Abe, Shoya Mizuno, Sayaka Furuhashi, Sayumi Hiraguri, Moeko Momokita, Tetsushi Oguma, Atsushi Nakayama, Hiroki Inoue

PMC · DOI: 10.3390/dj14020073 · 2026-02-02

## TL;DR

This paper explores the use of ORAPLA, an oral liquid bandage, to manage oral mucosal wounds and finds it provides immediate pain relief and protection.

## Contribution

The study introduces ORAPLA as a practical clinical solution for managing oral mucosal wounds with immediate protective effects.

## Key findings

- ORAPLA formed a protective film that lasted 5–6 hours and was well tolerated.
- Patients experienced prompt pain relief with no adverse events observed.
- Epithelialization occurred without secondary infection during follow-up.

## Abstract

Background/Objectives: Oral mucosal wounds are frequently encountered in daily dental practice and are often difficult to manage because of continuous exposure to saliva, mastication, and mechanical irritation. This technical note describes the clinical practicality of an oral liquid bandage (ORAPLA) as a film-forming protective barrier for traumatic and surgical oral mucosal wounds. Methods: ORAPLA was applied in four clinical scenarios: a traumatic lip bite injury, a postoperative mucosal defect following leukoplakia excision, a biopsy wound for suspected oral squamous cell carcinoma (OSCC), and aphthous stomatitis. Clinical observations included patient-reported symptom relief, film retention, and the clinical appearance of epithelialization at follow-up (1–2 weeks). Results: In all cases, ORAPLA formed a thin protective film immediately after application and was typically observed to remain on the wound surface for approximately 5–6 h under routine daily activities. Patients reported prompt subjective pain relief, and no adverse events were observed. Epithelialization proceeded without clinically evident secondary infection during the follow-up period. Conclusions: In this small descriptive case series, ORAPLA was feasible to apply, well tolerated, and provided temporary mechanical protection with immediate subjective comfort. Controlled studies using standardized outcome measures are warranted.

## Linked entities

- **Diseases:** leukoplakia (MONDO:0043243), oral squamous cell carcinoma (MONDO:0004958), aphthous stomatitis (MONDO:0004845)

## Full-text entities

- **Diseases:** immune-mediated disorders (MESH:C567355), dysarthria (MESH:D004401), bleeding (MESH:D006470), Oral Mucosal Disease (MESH:D009059), OSCC (MESH:D000077195), sleep disturbance (MESH:D012893), pain (MESH:D010146), taste disturbance (MESH:D013651), inflammatory (MESH:D007249), Mucosal Wounds (MESH:D014947), graft-versus-host disease (MESH:D006086), atrophy (MESH:D001284), swelling (MESH:D004487), cancer (MESH:D009369), Oral lichen planus (MESH:D017676), irritation (MESH:D001523), Bite Injury (MESH:D001733), allergic reaction (MESH:D004342), Oral (MESH:D020820), postoperative (MESH:D019106), Mucositis (MESH:D052016), impaired oral function (MESH:D003072), Aphthous Stomatitis (MESH:D013281), Leukoplakia (MESH:D007971), erythema (MESH:D004890), nutritional deficiencies (MESH:D044342), dysphagia (MESH:D003680), inflammatory ulceration (MESH:D014456), oral mucosal disorders (MESH:D013280), cytotoxicity (MESH:D064420), erosions (MESH:D014077), salivary dysfunction (MESH:D012466), infection (MESH:D007239)
- **Chemicals:** polymer (MESH:D011108), carbomer (MESH:C479038), ORAPLA (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939374/full.md

---
Source: https://tomesphere.com/paper/PMC12939374